Financial Ratios Revolution Medicines, Inc.
Equities
RVMD
US76155X1000
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 118.64 USD | +0.94% |
|
-3.64% | +49.13% |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | -17.56 | -18 | -20.83 | -20.08 | -18.66 | |||
Return on Total Capital | -20.96 | -19.97 | -22.76 | -21.67 | -19.97 | |||
Return On Equity % | -34.49 | -34.74 | -38.63 | -34.75 | -29.33 | |||
Return on Common Equity | -68.54 | -34.74 | -38.63 | -34.75 | -29.33 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | -207.68 | -536.09 | -615.3 | -3.45K | - | |||
SG&A Margin | 49.85 | 103.61 | 114.71 | 535.59 | - | |||
EBITDA Margin % | -251.54 | -629.32 | -718.88 | -3.94K | - | |||
EBITA Margin % | -257.61 | -639.81 | -730.1 | -3.99K | - | |||
EBIT Margin % | -257.54 | -639.7 | -730.01 | -3.99K | - | |||
Income From Continuing Operations Margin % | -251.63 | -636.58 | -702.95 | -3.77K | - | |||
Net Income Margin % | -251.63 | -636.58 | -702.95 | -3.77K | - | |||
Net Avail. For Common Margin % | -256.79 | -636.58 | -702.95 | -3.77K | - | |||
Normalized Net Income Margin | -157.81 | -397.86 | -440.09 | -2.24K | - | |||
Levered Free Cash Flow Margin | -135.53 | -288.16 | -375.46 | -1.34K | - | |||
Unlevered Free Cash Flow Margin | -135.43 | -288.14 | -375.46 | -1.34K | - | |||
Asset Turnover | ||||||||
Asset Turnover | 0.11 | 0.05 | 0.05 | 0.01 | - | |||
Fixed Assets Turnover | 1.98 | 0.55 | 0.49 | 0.13 | - | |||
Receivables Turnover (Average Receivables) | 5.68 | 4.77 | 6.67 | 3.91 | - | |||
Short Term Liquidity | ||||||||
Current Ratio | 9.63 | 9.77 | 10.65 | 13.06 | 14.2 | |||
Quick Ratio | 9.48 | 9.66 | 10.48 | 12.89 | 13.97 | |||
Operating Cash Flow to Current Liabilities | -2.12 | -2.44 | -3.62 | -2.44 | -3.4 | |||
Days Sales Outstanding (Average Receivables) | 64.42 | 76.51 | 54.69 | 93.41 | - | |||
Average Days Payable Outstanding | 33.22 | 26.03 | 25.5 | 36.87 | 35.91 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | 6.89 | 11.06 | 9.37 | 4.82 | 6 | |||
Total Debt / Total Capital | 6.44 | 9.96 | 8.57 | 4.59 | 5.66 | |||
LT Debt/Equity | 6.11 | 10.03 | 8.38 | 4.41 | 5.43 | |||
Long-Term Debt / Total Capital | 5.71 | 9.03 | 7.66 | 4.21 | 5.12 | |||
Total Liabilities / Total Assets | 16.34 | 18.35 | 15.61 | 11.42 | 11.46 | |||
EBIT / Interest Expense | -1.56K | -15.67K | - | -1.52K | - | |||
EBITDA / Interest Expense | -1.48K | -15.13K | - | -1.48K | - | |||
(EBITDA - Capex) / Interest Expense | -1.53K | -15.67K | - | -1.51K | - | |||
Total Debt / EBITDA | -0.31 | -0.37 | -0.26 | -0.2 | -0.2 | |||
Net Debt / EBITDA | 3.87 | 2.81 | 2.34 | 3.94 | 3.21 | |||
Total Debt / (EBITDA - Capex) | -0.3 | -0.35 | -0.25 | -0.19 | -0.2 | |||
Net Debt / (EBITDA - Capex) | 3.77 | 2.71 | 2.24 | 3.87 | 3.16 | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | -14.1 | -31.62 | 20.38 | -67.27 | - | |||
Gross Profit, 1 Yr. Growth % | 114 | 76.5 | 38.17 | 83.59 | 48.18 | |||
EBITDA, 1 Yr. Growth % | 108.41 | 71.07 | 37.51 | 79.55 | 49.56 | |||
EBITA, 1 Yr. Growth % | 104.48 | 69.82 | 37.37 | 78.75 | 49.35 | |||
EBIT, 1 Yr. Growth % | 104.54 | 69.84 | 37.38 | 78.75 | 49.35 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | 126.92 | 72.98 | 32.93 | 75.46 | 37.52 | |||
Net Income, 1 Yr. Growth % | 126.92 | 72.98 | 32.93 | 75.46 | 37.52 | |||
Normalized Net Income, 1 Yr. Growth % | 108.56 | 72.39 | 33.16 | 66.34 | 44.99 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | -90.99 | 27.75 | 20.04 | 25.02 | -7.23 | |||
Accounts Receivable, 1 Yr. Growth % | -26.83 | -7.26 | -21.18 | -73.16 | - | |||
Net Property, Plant and Equip., 1 Yr. Growth % | 408.42 | 96.04 | 3.51 | 35.64 | 41.8 | |||
Total Assets, 1 Yr. Growth % | 157.29 | 30.06 | 10.02 | 153.93 | 24.09 | |||
Tangible Book Value, 1 Yr. Growth % | -274.14 | 32.31 | 15.85 | 186.68 | 25.09 | |||
Common Equity, 1 Yr. Growth % | -411.11 | 26.94 | 13.71 | 166.52 | 24.04 | |||
Cash From Operations, 1 Yr. Growth % | 101.68 | 47.09 | 52.47 | 56.23 | 59.01 | |||
Capital Expenditures, 1 Yr. Growth % | 13.29 | 122.57 | 65.69 | -28.54 | 33.37 | |||
Levered Free Cash Flow, 1 Yr. Growth % | 743.3 | 45.42 | 56.85 | 16.84 | 124.02 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | 750.81 | 45.52 | 56.86 | 16.7 | 124.29 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | 46 | -23.36 | -9.27 | -37.23 | - | |||
Gross Profit, 2 Yr. CAGR % | 69.92 | 94.35 | 56.16 | 59.27 | 64.94 | |||
EBITDA, 2 Yr. CAGR % | 67.87 | 88.82 | 53.38 | 57.13 | 63.87 | |||
EBITA, 2 Yr. CAGR % | 66.52 | 86.35 | 52.74 | 56.7 | 63.39 | |||
EBIT, 2 Yr. CAGR % | 66.5 | 86.38 | 52.75 | 56.71 | 63.39 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 60.88 | 98.12 | 51.64 | 52.72 | 55.33 | |||
Net Income, 2 Yr. CAGR % | 60.88 | 98.12 | 51.64 | 52.72 | 55.33 | |||
Normalized Net Income, 2 Yr. CAGR % | 61.93 | 89.61 | 51.51 | 48.83 | 55.3 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | -69.22 | -66.07 | 23.84 | 22.51 | 7.69 | |||
Accounts Receivable, 2 Yr. CAGR % | -6.44 | -17.62 | -14.5 | -54.01 | - | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | 129.95 | 215.71 | 42.45 | 18.49 | 38.69 | |||
Total Assets, 2 Yr. CAGR % | 82.38 | 82.93 | 19.62 | 67.14 | 77.51 | |||
Tangible Book Value, 2 Yr. CAGR % | 46.44 | 51.79 | 23.81 | 82.24 | 89.37 | |||
Common Equity, 2 Yr. CAGR % | 109.24 | 98.73 | 20.15 | 74.09 | 81.82 | |||
Cash From Operations, 2 Yr. CAGR % | 808.26 | 72.23 | 49.75 | 54.33 | 57.61 | |||
Capital Expenditures, 2 Yr. CAGR % | 39.88 | 58.79 | 92.03 | 8.81 | -2.38 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | 87.43 | 250.13 | 51.03 | 35.37 | 61.78 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 87.76 | 251.81 | 51.08 | 35.3 | 61.78 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % | - | 13.38 | -10.91 | -35.41 | - | |||
Gross Profit, 3 Yr. CAGR % | 49.74 | 72.08 | 73.46 | 64.82 | 55.48 | |||
EBITDA, 3 Yr. CAGR % | 53.42 | 68.93 | 69.88 | 61.65 | 54.57 | |||
EBITA, 3 Yr. CAGR % | 52.65 | 67.61 | 68.34 | 60.96 | 54.21 | |||
EBIT, 3 Yr. CAGR % | 52.64 | 67.61 | 68.36 | 60.97 | 54.21 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % | 51.46 | 64.82 | 73.45 | 59.2 | 47.48 | |||
Net Income, 3 Yr. CAGR % | 51.46 | 64.82 | 73.45 | 59.2 | 47.48 | |||
Normalized Net Income, 3 Yr. CAGR % | 51.64 | 65.34 | 68.54 | 56.3 | 47.54 | |||
Diluted EPS Before Extra, 3 Yr. CAGR % | -53.68 | -50.54 | -48.3 | 24.23 | 11.66 | |||
Accounts Receivable, 3 Yr. CAGR % | - | -6.71 | -18.83 | -41.9 | - | |||
Net Property, Plant and Equip., 3 Yr. CAGR % | 90.54 | 118.04 | 117.7 | 40.14 | 25.8 | |||
Total Assets, 3 Yr. CAGR % | 235.11 | 62.94 | 54.41 | 53.74 | 51.34 | |||
Tangible Book Value, 3 Yr. CAGR % | 80.64 | 41.57 | 38.72 | 63.79 | 60.76 | |||
Common Equity, 3 Yr. CAGR % | 91.38 | 77.13 | 64.98 | 56.69 | 55.49 | |||
Cash From Operations, 3 Yr. CAGR % | 58.46 | 395.07 | 65.37 | 51.88 | 55.88 | |||
Capital Expenditures, 3 Yr. CAGR % | 23.03 | 63.3 | 61.06 | 38.12 | 16.45 | |||
Levered Free Cash Flow, 3 Yr. CAGR % | - | 72.21 | 167.91 | 38.64 | 60.12 | |||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | 72.45 | 168.77 | 38.62 | 60.13 | |||
Compound Annual Growth Rate Over Five Years | ||||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | -10.5 | - | |||
Gross Profit, 5 Yr. CAGR % | - | - | 52.28 | 66.84 | 70 | |||
EBITDA, 5 Yr. CAGR % | - | - | 53.4 | 64.11 | 67.45 | |||
EBITA, 5 Yr. CAGR % | - | - | 52.68 | 63.16 | 66.34 | |||
EBIT, 5 Yr. CAGR % | - | - | 52.68 | 63.16 | 66.36 | |||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | 51.53 | 59.87 | 65.96 | |||
Net Income, 5 Yr. CAGR % | - | - | 51.53 | 59.87 | 65.96 | |||
Normalized Net Income, 5 Yr. CAGR % | - | - | 51.58 | 58.53 | 63.11 | |||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | -31.36 | -28.91 | -30.66 | |||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | -29.7 | - | |||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | 69.61 | 70.84 | 81.77 | |||
Total Assets, 5 Yr. CAGR % | - | - | 121.94 | 64.61 | 63.27 | |||
Tangible Book Value, 5 Yr. CAGR % | - | - | 55.3 | 56.62 | 57.11 | |||
Common Equity, 5 Yr. CAGR % | - | - | 58.86 | 75.91 | 71.52 | |||
Cash From Operations, 5 Yr. CAGR % | - | - | 54.92 | 210.59 | 62.22 | |||
Capital Expenditures, 5 Yr. CAGR % | - | - | 47.01 | 38.82 | 31.83 | |||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 56.4 | 118.96 | |||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 56.5 | 119.38 |
- Stock Market
- Equities
- RVMD Stock
- Financials Revolution Medicines, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















